1. Home
  2. BDSX vs GNLX Comparison

BDSX vs GNLX Comparison

Compare BDSX & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Biodesix Inc.

BDSX

Biodesix Inc.

HOLD

Current Price

$22.98

Market Cap

153.3M

Sector

Health Care

ML Signal

HOLD

Logo Genelux Corporation

GNLX

Genelux Corporation

HOLD

Current Price

$2.88

Market Cap

133.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BDSX
GNLX
Founded
2005
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Precision Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
153.3M
133.0M
IPO Year
2020
2022

Fundamental Metrics

Financial Performance
Metric
BDSX
GNLX
Price
$22.98
$2.88
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
4
Target Price
$32.50
$17.25
AVG Volume (30 Days)
78.7K
169.4K
Earning Date
05-04-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
9.47
EPS
N/A
N/A
Revenue
$88,499,000.00
$8,000.00
Revenue This Year
$25.26
N/A
Revenue Next Year
$19.15
N/A
P/E Ratio
N/A
N/A
Revenue Growth
24.08
N/A
52 Week Low
$0.33
$2.29
52 Week High
$24.92
$8.54

Technical Indicators

Market Signals
Indicator
BDSX
GNLX
Relative Strength Index (RSI) 62.97 46.82
Support Level $13.41 $2.73
Resistance Level $24.92 $2.94
Average True Range (ATR) 1.88 0.12
MACD -0.09 -0.00
Stochastic Oscillator 77.10 33.33

Price Performance

Historical Comparison
BDSX
GNLX

About BDSX Biodesix Inc.

Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.

About GNLX Genelux Corporation

Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.

Share on Social Networks: